Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 38 for

Edit search filters
  1. Cara CDRM (Conduction Disturbance Risk Monitor) 2.0

    Rochester, MN

  2. An Evolut™ EXPAND TAVR II Pivotal Trial

    Rochester, MN

  3. ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

    Rochester, MN

  4. Left Ventricular Ejection Hemodynamics in Patients with Hypertrophic Cardiomyopathy and Valvular Aortic Stenosis

    Rochester, MN

  5. Siegel TAVR In Aortic Severe Stenosis

    Rochester, MN

  6. A Study To Evaluate The Efficacy And Safety Of GDC-8264 In Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) And Major Adverse Kidney Events (MAKE)

    Rochester, MN

  7. CTSN Embolic Protection Trial

    Rochester, MN

  8. Avalus Ultra Post-Approval Study (PAS)

    Rochester, MN

  9. Cardiac Vascular Reconstruction DynaCT for TAVI Procedures

    Rochester, MN

  10. Grit as a Predictor of Outcomes in Transcatheter Valvular Therapeutic Candidates

    Rochester, MN

.

Mayo Clinic Footer